SKYEPHARMA, ENDO AGREE TO TERMINATE JOINT DEVELOPMENT OF PROPOFOL IDD-D FOR NORTH AMERICA

SkyePharma PLC announce that it has agreed with its North American partner Endo Pharmaceuticals (ENDP) to terminate the joint development of Propofol IDD-D, an injectable anesthetic and sedative that was licensed to Endo in December 2002.

Therapeutics Daily (http://www.therapeuticsdaily.com/news/article.cfm?contenttype=sentryarticle&contentvalue=918391&channelID=30)